Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00490191 · ClinicalTrials.gov registry record · Phase 4
Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 387
- Enrollment target
NCT00490191 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 387 participants.
The verdict
NCT00490191, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 387 participants
- Enrollment target
Study Summary
This study tested whether a dose regimen of growth hormone based on body weight is equivalent or better than starting with a low dose and gradually increasing the dose according to individual patient needs. Efficacy of the two regimens were assessed from changes in body fat measured by dual-energy x-ray absorptiometry (DXA) scanning, performed at the beginning of the study and at the completion of the study eight months later.
Interventions
- DRUG Somatropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 1999-01 |
| Est. Completion | 2001-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00490191
The ClinicalTrials.gov registry entry for NCT00490191 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 387 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Somatropin is the first listed.
NCT00490191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00490191 about?
NCT00490191 is a clinical study titled "Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency". This study tested whether a dose regimen of growth hormone based on body weight is equivalent or better than starting with a low dose and gradually increasing the dose according to individual patient needs. Efficacy of the two regimens were assessed from changes in body fat measured by dual-energy x...
What is the current status of trial NCT00490191?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 387 participants. The study started on 1999-01. Estimated completion is 2001-07.
What interventions are being tested in trial NCT00490191?
The interventions under investigation include: Somatropin (DRUG).
Who is sponsoring clinical trial NCT00490191?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.